The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive gains, the end of its exclusive rights opened the floodgates to generic https://sabrinabnkj666021.blogitright.com/42146993/the-copyright-and-big-pharma-a-volatile-investment